SCHEMBL1908175

SCHEMBL1908175

NC(=O)c1nccc(-c2ccccc2)c1N1CCC(=O)C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 3/20 0.36
ADORA2A P29274 1/20 0.35
MAP2K3 P46734 1/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 4/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
IKBKB O14920 2/20 0.35
CHUK O15111 1/20 0.34
IKBKE Q14164 1/20 0.34
PKMYT1 Q99640 1/20 0.34
CHEK2 O96017 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
F10 P00742 1/20 0.34
CASP1 P29466 1/20 0.33
MAP2K1 Q02750 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
DYRK1B Q9Y463 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1908177 0.81 ADORA2A (0.35) BCAT2ADORA2AMAP2K3KMT2AALDH1A1
SCHEMBL1900466 0.80 ADORA2A (0.38) BCAT2ADORA2AMAP2K3KMT2AALDH1A1
SCHEMBL23067311 0.72 MAP2K3 (0.50) BCAT2ADORA2AMAP2K3KMT2AALDH1A1
SCHEMBL979249 0.71 MAPK9 (0.38) BCAT2ADORA2AMAP2K3ALDH1A1IKBKB
SCHEMBL1905178 0.71 NUDT1 (0.43)
SCHEMBL23248737 0.71 PTPN11 (0.45)
SCHEMBL2848953 0.70 ADORA2A (0.46) BCAT2ADORA2AMAP2K3IKBKBCHUK
SCHEMBL30423145 0.68 ADORA2A (0.45) BCAT2ADORA2AMAP2K3KMT2AALDH1A1
SCHEMBL7417186 0.68 KDM4E (0.42) BCAT2ADORA2AMAP2K3MAPTIKBKB
SCHEMBL944492 0.68 ROCK2 (0.46) IKBKBCHEK2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124663-A1 SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRM4, GRIA4, GRIK4 BCAT2 3508/4885ADORA2A 187/4885MAP2K3 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.